CD73 complexes with emmprin to regulate MMP-2 production from co-cultured sarcoma cells and fibroblasts.
CD73
Emmprin
Fibroblasts
MMP-2
Sarcoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Sep 2019
12 Sep 2019
Historique:
received:
13
01
2019
accepted:
03
09
2019
entrez:
13
9
2019
pubmed:
13
9
2019
medline:
12
2
2020
Statut:
epublish
Résumé
Interaction between cancer cells and fibroblasts mediated by extracellular matrix metalloproteinase inducer (emmprin, CD147) is important in the invasion and proliferation of cancer cells. However, the exact mechanism of emmprin mediated stimulation of matrix metalloprotease-2 (MMP-2) production from fibroblasts has not been elucidated. Our previous studies using an inhibitory peptide against emmprin suggested the presence of a molecule on the cell membrane which forms a complex with emmprin. Here we show that CD73 expressed on fibroblasts interacts with emmprin and is a required factor for MMP-2 production in co-cultures of sarcoma cells with fibroblasts. CD73 along with CD99 was identified by mass spectrometry analysis as an emmprin interacting molecule from a co-culture of cancer cells (epithelioid sarcoma cell line FU-EPS-1) and fibroblasts (immortalized fibroblasts cell line ST353i). MMP-2 production was measured by immunoblot and ELISA. The formation of complexes of CD73 with emmprin was confirmed by immunoprecipitation, and their co-localization in tumor cells and fibroblasts was shown by fluorescent immunostaining and proximity ligation assays. Stimulated MMP-2 production in co-culture of cancer cells and fibroblasts was completely suppressed by siRNA knockdown of CD73, but not by CD99 knockdown. MMP-2 production was not suppressed by CD73-specific enzyme inhibitor (APCP). However, MMP-2 production was decreased by CD73 neutralizing antibodies, suggesting that CD73-mediated suppression of MMP-2 production is non-enzymatic. In human epithelioid sarcoma tissues, emmprin was immunohistochemically detected to be mainly expressed in tumor cells, and CD73 was expressed in fibroblasts and tumor cells: emmprin and CD73 were co-localized predominantly on tumor cells. This study provides a novel insight into the role of CD73 in emmprin-mediated regulation of MMP-2 production.
Sections du résumé
BACKGROUND
BACKGROUND
Interaction between cancer cells and fibroblasts mediated by extracellular matrix metalloproteinase inducer (emmprin, CD147) is important in the invasion and proliferation of cancer cells. However, the exact mechanism of emmprin mediated stimulation of matrix metalloprotease-2 (MMP-2) production from fibroblasts has not been elucidated. Our previous studies using an inhibitory peptide against emmprin suggested the presence of a molecule on the cell membrane which forms a complex with emmprin. Here we show that CD73 expressed on fibroblasts interacts with emmprin and is a required factor for MMP-2 production in co-cultures of sarcoma cells with fibroblasts.
METHODS
METHODS
CD73 along with CD99 was identified by mass spectrometry analysis as an emmprin interacting molecule from a co-culture of cancer cells (epithelioid sarcoma cell line FU-EPS-1) and fibroblasts (immortalized fibroblasts cell line ST353i). MMP-2 production was measured by immunoblot and ELISA. The formation of complexes of CD73 with emmprin was confirmed by immunoprecipitation, and their co-localization in tumor cells and fibroblasts was shown by fluorescent immunostaining and proximity ligation assays.
RESULTS
RESULTS
Stimulated MMP-2 production in co-culture of cancer cells and fibroblasts was completely suppressed by siRNA knockdown of CD73, but not by CD99 knockdown. MMP-2 production was not suppressed by CD73-specific enzyme inhibitor (APCP). However, MMP-2 production was decreased by CD73 neutralizing antibodies, suggesting that CD73-mediated suppression of MMP-2 production is non-enzymatic. In human epithelioid sarcoma tissues, emmprin was immunohistochemically detected to be mainly expressed in tumor cells, and CD73 was expressed in fibroblasts and tumor cells: emmprin and CD73 were co-localized predominantly on tumor cells.
CONCLUSION
CONCLUSIONS
This study provides a novel insight into the role of CD73 in emmprin-mediated regulation of MMP-2 production.
Identifiants
pubmed: 31510956
doi: 10.1186/s12885-019-6127-x
pii: 10.1186/s12885-019-6127-x
pmc: PMC6739984
doi:
Substances chimiques
BSG protein, human
0
Biomarkers
0
GPI-Linked Proteins
0
Basigin
136894-56-9
5'-Nucleotidase
EC 3.1.3.5
NT5E protein, human
EC 3.1.3.5
Matrix Metalloproteinase 2
EC 3.4.24.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
912Références
Cancer Lett. 2000 Sep 1;157(2):177-84
pubmed: 10936678
Int J Cancer. 2000 Oct 1;88(1):21-7
pubmed: 10962435
Cancer Res. 2001 Mar 1;61(5):2276-81
pubmed: 11280798
Int J Cancer. 2002 Jun 1;99(4):520-8
pubmed: 11992541
Curr Top Dev Biol. 2003;54:371-89
pubmed: 12696756
J Biol Chem. 2004 Mar 19;279(12):11112-8
pubmed: 14707126
Exp Cell Res. 2004 Feb 15;293(2):259-66
pubmed: 14729463
Mol Biol Cell. 2004 Sep;15(9):4043-50
pubmed: 15201341
Cancer Res. 2005 Apr 15;65(8):3193-9
pubmed: 15833850
Mol Cell Proteomics. 2005 Aug;4(8):1061-71
pubmed: 15901826
Int J Oncol. 2005 Aug;27(2):361-9
pubmed: 16010416
Pathol Int. 2006 Jul;56(7):359-67
pubmed: 16792544
J Biol Chem. 2006 Nov 17;281(46):34833-47
pubmed: 16984917
J Biol Chem. 2006 Dec 8;281(49):37576-85
pubmed: 17050542
Int J Cancer. 2007 Feb 15;120(4):761-8
pubmed: 17131322
Cancer Res. 2007 May 1;67(9):4182-9
pubmed: 17483329
Clin Exp Metastasis. 2007;24(6):439-48
pubmed: 17587186
Cancer Sci. 2010 Feb;101(2):387-95
pubmed: 20047591
Int J Oncol. 2011 Sep;39(3):657-64
pubmed: 21637915
J Biol Chem. 1990 Dec 5;265(34):21141-51
pubmed: 2174435
BMC Cancer. 2011 Jul 17;11:300
pubmed: 21762534
Hepatology. 2011 Dec;54(6):2012-24
pubmed: 21809360
J Surg Oncol. 2012 Aug 1;106(2):130-7
pubmed: 22287455
Int J Cancer. 2012 Nov 15;131(10):2264-73
pubmed: 22392539
J Surg Oncol. 2012 Dec;106(7):918-9; author reply 920
pubmed: 22585744
Virchows Arch. 2012 Oct;461(4):457-66
pubmed: 22926487
Cancer Res. 2013 Jan 1;73(1):172-83
pubmed: 23135911
PLoS One. 2013;8(1):e53710
pubmed: 23326490
World J Gastroenterol. 2013 Mar 28;19(12):1912-8
pubmed: 23569336
Pathol Oncol Res. 2013 Oct;19(4):811-4
pubmed: 23653114
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11091-6
pubmed: 23776241
Biomed J. 2014 Jul-Aug;37(4):169-77
pubmed: 25116711
Biomed Res Int. 2014;2014:460654
pubmed: 25126561
Clin Cancer Res. 2016 Jan 1;22(1):158-66
pubmed: 26253870
Cancer Res. 2015 Nov 1;75(21):4494-503
pubmed: 26363007
Biosci Rep. 2015 Nov 24;36(1):e00283
pubmed: 26604323
J Biochem. 2016 May;159(5):481-90
pubmed: 26684586
Virchows Arch. 2016 Jul;469(1):25-34
pubmed: 27056569
Oncotarget. 2016 Sep 20;7(38):61690-61702
pubmed: 27557512
Int J Oncol. 2017 Jun;50(6):2229-2235
pubmed: 28498412
Cancer Res. 1995 Jan 15;55(2):434-9
pubmed: 7812975
FASEB J. 1993 Dec;7(15):1434-41
pubmed: 8262328
Cancer Res. 1993 Jul 1;53(13):3154-8
pubmed: 8319225
Int J Cancer. 1993 Aug 19;55(1):19-26
pubmed: 8344748
J Biol Chem. 1997 Jan 3;272(1):24-7
pubmed: 8995219
J Biol Chem. 1997 Nov 14;272(46):29174-80
pubmed: 9360995